Long-term results of irritable bowel syndrome treatment

Aim of investigation. To estimate duration of remission of irritable bowel syndrome after treatment by multistrain probiotic drug, motility regulator or antispasmodic medication. Material and methods. Original study included overall 87 patients with irritable bowel syndrome (IBS) or IBS in combination with functional dyspepsia (FD) in whom the diagnosis was confirmed according to compliance of symptoms to the Rome-III criteria and absence of organic diseases according to laboratory and instrumental investigation. In 42 patients diarrheapredominant variant of IBS was diagnosed (IBS-D), in 45 patients - constipation-predominant (IBS-C). All patients enrolled in original study underwent monotherapy by probiotic agent, motility regulator trimebutine or spasmolytic drug. The probiotic agent (Bifidobacterium bifidum, B. longum, B. infantis, Lactobacillus rhamnosus) was prescribed to 15 patients with IBS-D and 15 patients with IBS-C, motility regulator (trimebutine) - respectively to 12 and 15 patients, antispasmodic was used in 15 patients with IBS-D and 15 - with IBS-C. All patients at the end of 28thday of treatment achieved clinical remission of the disease (decrease of the total score of «7×7» Questionnaire for 50% and more). At the 30, 45 and 60 days after treatment secession in patients had telephone interview with health-related questions. Patients’ responses of those who received no maintenance therapy were statistically analyzed. Results. In 30 days secession of pharmaceutical therapy 73.3% of patients with IBS-D who received probiotic therapy during relapse maintained clinical remission, 75% of patients often motility regulator treatment and 60% of those who received antispasmodic medications. Of patients with IBS-C in 30 days after treatment termination remission was maintained in 60% of those after probiotic treatment, in 80% of the motility regulator treatment and in 60% antispasmodic therapy. In 45 days 47% of IBS-D patients treated by probiotics had sense of well-being, 58% of those who received motility regulators and 47% of patients who received antispasmodics previously. Of IBS-C patients in 1.5 months 33.3% of those, who received probiotic were symptomless, 46,3% of patients after trimebutine therapy and 33,3% of patients who achieved remission after antispasmodic therapy. In 60 days of IBS-D 20% in the group of patients remained in remission after probiotic treatment, 20% after trimebutine therapy and 33% after antispasmodic. Of IBS-C patients 20, 33 and 20% of patients respectively maintained clinical remission. No statistically significant differences between groups of patients with IBS-D and IBS-C were revealed (р>0.05). Conclusion. According to the obtained data, pharmacologically induced remission in the most of IBS cases is short-term. Remission duration depend neither on clinical variant of disease, nor on the group of drugs applied for remission induction.

синдром раздраженного кишечника, пробиотики, спазмолитики

1. Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel Disorders. Gastroenterology 2016;150:1393-407.

2. Perveen I., Rahman M.M., Saha M. et.al. Prevalence of irritable bowel syndrome and functional dyspepsia, overlapping symptoms, and associated factors in a general population of Bangladesh. Indian J Gastroenterol 2014 May;33(3):265-73.

3. Vakil N., Stelwagon M. Shea E.P. Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population. United Eur Gastroenterol J 2016 Jun;4(3):413-22.

4. Ивашкин В.Т., Полуэктова Е.А., Рейхарт Д.В., Шифрин О.С., Бениашвили А.Г., Ляшенко О.С., Белостоцкий А.В. Эффективность наиболее часто назначаемых групп препаратов у пациентов с функциональными расстройствами желудочно-кишечного тракта - синдромом функциональной диспепсии и синдромом раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол 2016;26(4):14-23.

5. Lee B.J., Bak Y.T. Irritable bowel syndrome, gut microbiota and probioticsю J Neurogastroenterol Motil 2011;17: 252-66.

6. Юрманова Е.Н. Отдаленные результаты лечения и прогноз пациентов с синдромом раздражённого кишечника: Дис. … канд. мед. наук. М.; 2007.

7. Kleinstäuber M., Witthöft M., Steffanowski A., van Marwijk H., Hiller W., Lambert M.J. Pharmacological interventions for somatoform disorders in adults. Cochrane Database Syst Rev 2014 Nov 7;(11):CD010628.

8. Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации, Ассоциации колопроктологов России по диагностике и лечению больных с синдромом раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол 2014;24(2):92-101.

9. Ивашкин В.Т., Шептулин А.А., Лапина Т.Л. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению функциональной диспепсии. Рос журн гастроэнтерол гепатол колопроктол 2012;22(3):80-92.

10. Ивашкин В.Т., Шептулин А.А., Полуэктова Е.А., Рейхарт Д.В., Белостоцкий А.В., Дроздова А.А., Арнаутов В.С. Возможности применения опросника «7×7» (7 симптомов за 7 дней) для оценки динамики симптомов функциональной диспепсии и синдрома раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол 2016; 26(3):24-32.

11. Jeffery I.B., O’Toole P.W., Öhman L., Claesson M.J., Deane J., Quigley E.M., Simrén M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012 Jul;61(7):997-1006.

12. Pozuelo M., Panda S., Santiago A. Reduction of butyrateand methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci Rep 2015 Aug 4;5:12693.

13. Spiller R., Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil 2012;18:258-68.

14. Ивашкин В.Т., Полуэктова Е.А. Функциональные расстройства желудочно-кишечного тракта. М.: МЕДпрессинформ; 2013.

15. Cash B.D., Chey W.D. Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipation. Aliment Pharmacol Ther 2005; 22(11):1047-60.

16. Fichna J., Poole D., Veldhuis N. Transient receptor potential vanilloid 4 inhibits mouse colonic motility by activating NO-dependent enteric neurotransmission. J Mol Med (Berl) 2015 Dec;93(12):1297-309.

17. Sarkar Amar et.al. Psychobiotics and the Manipulation of Bacteria-Gut-Brain Signals. Trends Neurosci 2016 Nov;39(11):763-81.

18. Barrett E., Ross R.P., O’Toole P.W., Fitzgerald G.F., Stanton C. γ-Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol2012;113(2):411-7.